TONIX PHARMACEUTICALS HLDG Q2 2026 Earnings Preview: Recent $TNXP Insider Trading, Hedge Fund Activity, and More
Tonix Pharmaceuticals Holding (TNXP) is expected to report Q2 2026 earnings on Aug. 10 before market open, according to Finnhub. Analysts forecast revenue of $7,876,950 and EPS of -$2.75. The article cites recent TNXP insider purchases and 13F activity, plus two analysts’ price targets with a $24.0 median.
How this was made
The 30-second read
Why it matters
The actionable element is the scheduled earnings timing plus consensus revenue and EPS figures, which define the immediate “beat or miss” setup for TNXP.
Market read
Traders can use the stated consensus estimates and release timing to plan options/position sizing and volatility expectations into the Aug 10 pre-market print.
What to watch
The article does not discuss pipeline milestones, trial readouts, cash runway, or guidance details, which are typically the true drivers of biotech earnings reactions.
Background
The piece is an earnings preview for Tonix Pharmaceuticals ahead of its Aug 10 pre-market Q2 2026 report, supplemented with insider trading and institutional holdings activity.
Ticker impact
Tonix Pharmaceuticals is set to report Q2 2026 earnings Aug 10 before the open, with consensus revenue of $7.88M and EPS of -$2.75.
Potential volatility around the Aug 10 pre-market release, with direction dependent on whether reported revenue and EPS beat or miss the $7.88M and -$2.75 expectations.
The article provides a concrete upcoming earnings date and consensus estimates, but it does not include any new company-specific operational update beyond insider/13F-style flows.
Market effects
As a small-cap biotech earnings event, it can contribute to sentiment in the broader development-stage pharma tape, but the article provides no sector-wide catalyst.
No specific regional linkage beyond US pre-market earnings timing.
Limited, since the disclosure is company-specific and US-focused.
Counterpoint
Insider buying and some institutional adds may be interpreted as supportive, but these flows are not a substitute for an earnings beat, especially with consensus EPS deeply negative.
Key entities
- companyTONIX PHARMACEUTICALS HLDG
Subject of the article, scheduled to report Q2 2026 earnings on Aug 10 before market open.
- insiderSeth Lederman
CEO cited as making three open-market purchases in the prior six months.
- institutionPoint72 Asset Management, L.P.
Cited as removing 494,619 shares (-79.8%) in Q1 2026.
